Novo Nordisk's Victoza (liraglutide), the first glucagon-like peptide-1 receptor agonist subcutaneous injection, received FDA approval for the treatment of type 2 diabetes mellitus.
Laura Moretti Challen, PharmD, BCPS
Advertisement
Articles by Laura Moretti Challen, PharmD, BCPS
Onglyza (saxagliptin) comarketed by Bristol-Myers Squibb and AstraZeneca, is FDA-approved to improve glycemic control for the treatment of type 2 diabetes.
Advertisement
Latest Updated Articles
- Rx Product News Profile: A Closer Look at New FDA Actions: Novo Nordisk's Victoza
Published: June 15th 2010 | Updated:
- Rx Product News Profile: A Closer Look at New FDA Actions: Bristol-Myers Squibb's and AstraZeneca's Onglyza
Published: May 11th 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
2
Celebrating the Pharmacist’s Impact: How Pharmacists Elevate Care in Every Setting
3
FDA Approves 1-Minute HIV Self-Test
4
How Pharmacists Can Navigate Legal Complexities With Most Favored Nation Status
5
